Abaxis Selects Vetter Software to offer Veterinary Practices a complete cloud based solution
Companies also announce Co-Marketing and technology partnership with Silicon Valley based Vetter Software
UNION CITY, Calif., Oct. 22, 2015 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide, announced today that a co-marketing and technology partnership has been reached with Vetter Software, which names Vetter Software's cloud veterinary practice management solution as Abaxis' preferred practice management solution.
As part of the partnership, Abaxis will co-market and re-sell Vetter Software's solution globally. The integration between the companies' products automatically imports results from Abaxis' blood analyzers into a clinic's Vetter Software account, which significantly reduces the amount of time spent by clinic staff to manually import results into a patient's records.
"Cloud technology is disrupting every aspect of veterinary diagnostics," said Sagi Solomon, Chief Executive Officer and Founder of Vetter Software. "Veterinary Hospitals are demanding that data from every aspect of their practices be available to them in real-time from anywhere. Our partnership with Abaxis answers this call by leveraging the power of the cloud to make blood results from Abaxis on-site analyzers available to practitioners in their Vetter Software accounts, which can be accessed from any device with an Internet connection."
Abaxis' Vice President of Sales and Marketing, Dr. Craig Tockman states "The point-of-care laboratory is a critical aspect of veterinary practice both medically and financially. Data management is not only important for the electronic patient record, but for client communication, workflow and billing. This agreement allows Abaxis to offer state of the art cloud based solutions to our chemistry and hematology customers while providing greater accessibility to view point-of-care laboratory results on any device. Abaxis customers can now optimally manage their laboratory, provide optimal client communication and enhance their workflow while providing the most accurate and precise results from the best analyzers available in the market."
"Vetter Software has allowed our burgeoning ophthalmology practice to run paperless, and with increased efficiency," said Dr. Patrick McCallum, owner of Vision Care for Animals, a specialty practice based in Palo Alto, California. "We appreciate the latest integration with Abaxis, it is keeping our in-house clinical chemistry results at our fingertips the moment we need it."
About Vetter Software
Vetter Software is the leading cloud veterinary healthcare company. Our mission is to deliver innovation that helps coordinate and improve the care and health of the world's animals. Vetter Software was founded in 2011 and is based in Santa Clara, California. To learn more about Vetter Software, please visit www.vettersoftware.com. Follow us on Twitter @vettersoftware and like us on Facebook at https://www.facebook.com/VetterSoftware.
Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visithttp://www.abaxis.com.
Forward Looking Statements This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to risks related to the transition of its U.S. medical sales to Abbott, potential excess inventory levels and inventory imbalances at the company's distributors, losses or system failures with respect to Abaxis' facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition ofthe United States economy. Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10‑K, and subsequently filed quarterly reports on Form 10‑Q filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.